Background
Phase III, open-label RCT. N=477 patients with high-risk early TNBC after completing standard (neo)adjuvant chemotherapy and surgery. Two strata: Stratum A — high-risk resection with pCR (node-positive or T3–T4 at presentation; n=83); Stratum B — residual invasive disease after neoadjuvant chemotherapy (non-pCR; n=383). No prior immunotherapy. Italian multicenter design.
Interventions and follow up
Arm A: Avelumab (anti-PD-L1) 10 mg/kg IV q2wk for 12 months
Arm B: Observation (no active treatment)
Primary endpoint: Disease-free survival (DFS) in ITT population
mFollow up: 52.1 months
Arm B: Observation (no active treatment)
Primary endpoint: Disease-free survival (DFS) in ITT population
mFollow up: 52.1 months
Results
DFS (ITT): HR 0.81 (95% CI 0.61–1.09), P=.172 — not significant (negative primary endpoint)
DFS (Stratum B, non-pCR): HR 0.80 (95% CI 0.58–1.10), P=.170
OS (descriptive secondary): HR 0.66 (95% CI 0.45–0.97)
3-year OS: 84.8% vs 76.3%
DFS (Stratum B, non-pCR): HR 0.80 (95% CI 0.58–1.10), P=.170
OS (descriptive secondary): HR 0.66 (95% CI 0.45–0.97)
3-year OS: 84.8% vs 76.3%
Adverse events
Immune-related (avelumab arm): Grade ≥3 irAEs ~10%; thyroid dysfunction any grade ~20%
Infusion/discontinuation: infusion reactions reported; treatment discontinuation due to AEs ~15% in the avelumab arm
Infusion/discontinuation: infusion reactions reported; treatment discontinuation due to AEs ~15% in the avelumab arm
Conclusions
A-BRAVE did not meet its primary endpoint of DFS improvement with adjuvant avelumab in high-risk early TNBC (HR 0.81, P=.172). A descriptive OS signal (HR 0.66, 3-yr OS 84.8% vs 76.3%) was observed but must be interpreted as exploratory given the negative DFS result.
Key Limitations
Trial failed its primary DFS endpoint; all survival analyses are exploratory. The DFS–OS discordance is biologically unusual and may reflect differential salvage therapy, random variation, or a delayed immune effect in a modestly-sized trial. Stratum A (pCR, n=83) was severely underpowered. Single-country Italian design limits global generalizability. No biomarker enrichment (PD-L1, TILs) for patient selection.
Clinical Context
A-BRAVE is a negative trial; adjuvant avelumab will not enter practice for TNBC. The established post-neoadjuvant standard for non-pCR is adjuvant capecitabine (CREATE-X) or olaparib (OlympiA, for gBRCA carriers). Pembrolizumab is approved by FDA and EMA in the neoadjuvant+adjuvant setting (KEYNOTE-522). A-BRAVE's OS signal, if validated, could reopen the question of purely adjuvant checkpoint inhibition, but current data do not support practice change. ESMO-MCBS: negative trial (unscored).